Experts from the European Union’s drug regulatory agency say that the benefits of this dosage still outweigh the risks.
London- Experts from the European Medicines Regulatory Agency said on Tuesday that after a small number of cases were reported in the United States, they found a “possible link” between Johnson & Johnson’s Covid-19 vaccine and a very rare blood clot, but they confirmed this benefit. The vaccination rate still exceeds the recipient’s minimal risk of abnormal blood clots.
The European Medicines Agency said a warning about rare blood clots should be added to Johnson & Johnson’s COVID-19 vaccine label. The agency said these rare blood diseases should be considered “very rare side effects of the vaccine.”
Last week, Johnson & Johnson suspended its vaccine delivery in Europe after US officials recommended that the vaccine be suspended. At that time, they found six very rare blood clots among nearly 7 million vaccinated people.
European officials said they considered all the evidence currently available in the United States, including eight reports of severe platelet scarcity and low platelets, including one death.
Johnson & Johnson recommends that European governments store dosages until EU drug regulatory agencies issue guidelines for use. Injections have not yet been widely used in Europe.
Blood clots associated with the Johnson & Johnson vaccine occur in abnormal parts of the body, such as the veins that drain blood from the brain. These patients have abnormally low levels of platelets in the blood, which are usually related to bleeding, not coagulation.
Eleanor Riley, professor of immunology and infectious diseases at the University of Edinburgh, said: “There is growing suspicion that these rare cases may be caused by the adenovirus components of AstraZeneca and Johnson & Johnson vaccines.” He said, although more needs to be done A lot of data, but “for the vast majority of adults in Europe and the United States, the risk associated with contracting COVID-19 far exceeds the risk of vaccination.”